Halozyme Therapeutics, Inc. (HALO) Stock Forecast
HALO analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.33 / 5 from 9 analysts
- Price target
- $108.78 average of analyst targets
- Upside to target
- −10.7% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $2.16
- 52-week range
- $61.63 – $121.84
HALO analyst ratings
9 analystsNumber of analysts at each rating.
HALO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HALO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.35 | $2.33 | $2.37 | $1.72 | +36.7% | 6 |
| Current fiscal year (2026) | $8.84 | $8.65 | $8.95 | $4.15 | +112.9% | 6 |
| Next fiscal year (2027) | $10.68 | $10.11 | $11.27 | $8.84 | +20.8% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HALO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $490.8M | $482.0M | $496.0M | +38.6% | 7 |
| Current fiscal year (2026) | $1.88B | $1.86B | $1.91B | +34.7% | 9 |
| Next fiscal year (2027) | $2.10B | $1.99B | $2.22B | +11.7% | 8 |
HALO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HALO revenue: reported and forecast
HALO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.19 | $2.29 | $2.29 | $2.29 | $2.35 | +7.3% | 1 up · 0 down |
| Current fiscal year (2026) | $8.12 | $8.58 | $8.58 | $8.58 | $8.84 | +8.8% | 1 up · 0 down |
| Next fiscal year (2027) | $9.91 | $10.39 | $10.39 | $10.39 | $10.68 | +7.7% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HALO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HALO beat in 9 of 12.
What analysts expect from HALO
9 analysts cover Halozyme Therapeutics; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $108.78, 10.7% below the latest close of $121.84. Analysts expect earnings of $8.84 per share for 2026, +112.9% from a year earlier. For 2027 the average estimate is $10.68 per share on revenue of $2.1 billion. Halozyme Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: HALO income statement, HALO key metrics, HALO chart. See the HALO stock overview for the latest quote and news.
HALO forecast FAQ
What is Halozyme Therapeutics's price target?
The average analyst price target for Halozyme Therapeutics is $108.78, 10.7% below the latest close of $121.84.
Is Halozyme Therapeutics a buy, hold or sell?
Of 9 analysts covering Halozyme Therapeutics, 5 rate it a strong buy, 2 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Halozyme Therapeutics's EPS forecast?
Analysts forecast $8.84 per share for 2026 (range $8.65 to $8.95); for 2027 the estimate is $10.68.
What is Halozyme Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $1.9 billion, growth of 34.7%; for 2027 it is $2.1 billion.
When does Halozyme Therapeutics report earnings?
Halozyme Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes; the EPS estimate is $2.16.
Does Halozyme Therapeutics usually beat earnings estimates?
Halozyme Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.